It is made available under a CC-BY-NC-ND 4.0 International license .

1 Title

- 2 Is influenza B/Yamagata extinct and what public health implications could this have? An updated
- 3 literature review and comprehensive assessment of global surveillance databases.

4

- 5 Authors
- 6 Saverio Caini¹, Adam Meijer², Marta C. Nunes^{3,4,5}, Laetitia Henaff⁴, Malaika Zounon⁴,
- 7 Bronke Boudewijns¹, Marco Del Riccio^{1,6}, John Paget¹

8

9 ¹ Nivel (Netherlands Institute for Health Services Research), Utrecht, the Netherlands.

² National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

³ Center of Excellence in Respiratory Pathogens (CERP), Hospices Civils de Lyon, Lyon,
 France.

⁴ Centre International de Recherche en Infectiologie (Team Public Health, Epidemiology and
 Evolutionary Ecology of Infectious Diseases (PHE3ID)), Inserm U1111, CNRS UMR5308, ENS

- 15 de Lyon, Université Claude Bernard, Lyon 1, Lyon, France.
- ⁵ South African Medical Research Council, Vaccines & Infectious Diseases Analytics Research
- 17 Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
- ⁶ Department of Health Sciences, University of Florence, Florence, Italy.

19

20 Corresponding author

- 21 Saverio Caini
- 22 Netherlands Institute for Health Services Research (Nivel)
- 23 Otterstraat 118, 3513 CR Utrecht, the Netherlands.
- 24 Email address: <u>s.caini@nivel.nl</u>
- 25

It is made available under a CC-BY-NC-ND 4.0 International license .

26 Abstract

27 Introduction: Early after the start of the COVID-19 pandemic, a major drop in the number of 28 influenza B/Yamagata detections was observed globally. Given the potential public health 29 implications, particularly with regards to influenza vaccination, we conducted a systematic review of influenza B/Yamagata virus circulation data from multiple complementary sources of 30 information. Methods: We searched articles published until 20th March 2023 in PubMed and 31 32 EMBASE; examined epidemiological and virological influenza data for 2020-2023 contained in 33 the publicly available WHO-FluNet and GISAID (Global Initiative on Sharing All Influenza Data) global databases, or collected by the multi-national Global Influenza Hospital Surveillance 34 Network (GIHSN) study; and looked for influenza data in the webpages of respiratory viruses 35 surveillance systems from countries worldwide. Results: Highly consistent findings were found 36 across all sources of information, with a progressive decline of influenza B/Yamagata detections 37 from 2020 onwards across all world regions, both in absolute terms (total number of cases), the 38 39 positivity rate, and as a fraction of influenza B detections. Isolated influenza B/Yamagata cases continue to be sporadically reported, and these are typically vaccine-derived, mistaken data 40 entries or under investigation. Discussion: While it is still too early to conclude that B/Yamagata 41 42 is (or will soon become) extinct, the current epidemiological and virological data call for a rapid response in terms of influenza prevention practices, particularly regarding the formulation of 43 influenza vaccines. The current epidemiological situation is unprecedented in recent decades, 44 45 underlying the importance of continuously and carefully monitoring the circulation of influenza 46 viruses (as well as SARS-CoV-2 and the other respiratory viruses) in the coming years.

47 Keywords: Influenza virus; influenza B/Yamagata virus; surveillance; influenza vaccine.

It is made available under a CC-BY-NC-ND 4.0 International license .

49 Introduction

The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 50 and the resulting coronavirus disease (COVID-19) pandemic, including the public health 51 52 measures that were put in place to contain the spread of the virus, caused major disruptions to the circulation of influenza [Dhanasekaran 2022] and most other respiratory viruses. Early in the 53 course of the COVID-19 pandemic, the circulation of seasonal influenza viruses was drastically 54 reduced, with most countries around the world reporting significant declines in influenza 55 positivity rates (and, in some cases, only sporadic detections or even none at all) over the 56 following usual epidemic periods [Olsen 2020]. During 2022, influenza viruses gradually 57 resumed circulation [Merced-Morales 2022], although it is still to be determined whether the 58 pre-2020 pattern of circulation (e.g. typical timing of start, peak, and end of seasonal epidemics) 59 and burden of disease will be restored or instead changes will persist due to the co-circulation of 60 61 influenza and SARS-CoV-2.

While much uncertainty remains and predictions are difficult to make, one aspect that 62 quickly came to the attention of the scientific community was the strong decrease in the number 63 of detections of influenza B/Yamagata cases. In the years prior to the emergence of SARS-CoV-64 2, the B/Victoria and B/Yamagata virus lineages tended to circulate simultaneously globally, with 65 no clear or consistent pattern in the way the two lineages alternated from one season to another 66 (including mixed seasons) [Puzelli 2019]. Interestingly, B/Yamagata viruses were responsible for 67 68 a larger proportion of influenza B infections than B/Victoria globally during 2012-2017, but in the last two years prior to the COVID-19 pandemic (i.e. after the major outbreak of influenza 69 B/Yamagata in 2017-2018 in large parts of the world), the B/Victoria lineage had become largely 70 71 prevalent, and the B/Yamagata-to-B/Victoria ratio (calculated out of all influenza B cases that

were characterized) dropped to 1/4.5 in 2018 and 1/19.3 in 2019 [Zanobini 2022]. Early in the course of the COVID-19 pandemic, and even after influenza viruses started circulating again in 2021, B/Yamagata lineage viruses were detected in only a very few countries globally according to previous reports [Koutsakos 2021, Dhanasekaran 2022, Paget 2022], and the question arose as to whether B/Yamagata lineage viruses had gone extinct (or pushed close to extinction) by the pandemic.

78 It is premature to definitely declare the extinction of the B/Yamagata lineage; as viral circulation might be at low levels, sub-threshold compared to the capabilities of existing 79 80 surveillance systems or circulating in regions of the world currently not well covered by surveillance systems (e.g. West Africa), and there remains the possibility of a resurgence of the 81 B/Yamagata lineage in the future. Indeed, it is worth mentioning that during much of the 1990s 82 the B/Victoria lineage did not circulate in most regions of the world and was primarily confined 83 to East Asia, before spreading globally again in the early 2000s [Xu 2015]. The current 84 epidemiological situation holds significant implications for public health, particularly regarding 85 influenza vaccination strategies [Paget 2022, Dhanasekaran 2022]. Since quadrivalent 86 influenza vaccines (OIVs) contain virus strains from both B lineages, the question arises as to 87 88 whether it is appropriate to recommend a vaccine targeting a virus that is currently not circulating (regardless of cost-effectiveness considerations and potential hesitancy among the 89 90 population). Moreover, there is a concern that the mechanistic attenuated replication of the 91 B/Yamagata strains contained in the live attenuated influenza vaccine (LAIV), primarily 92 administered to children (e.g. UK, US and EU regions), could theoretically lead to reintroduction of the haemagglutinin (HA) (and neuraminidase (NA)) genes of a potentially extinct virus 93 through reassortment with a coinfecting wildtype B/Victoria lineage virus [Dudas 2015]. 94

It is made available under a CC-BY-NC-ND 4.0 International license .

95 Importantly, LAIV, when shedding, retains its cold-adapted nature and secondary infections after 96 vaccine-derived influenza B/Yamagata infections are unlikely and indeed have not been shown to 97 date [Vesikari 2006]. Continuous monitoring of viral circulation is therefore extraordinarily 98 important so that influenza prevention policies, especially those related to vaccine formulation 99 and composition, can be adapted and tailored to the current epidemiological landscape.

100 Here we aimed to study the circulation of B/Yamagata influenza viruses from 2020 101 onwards, in order to understand whether these viruses are extinct (or could become extinct soon) and discuss what public health implications this could have. For this purpose, we conducted a 102 103 comprehensive and systematic review of multiple data sources pertaining to the circulation of B/Yamagata influenza viruses. This updated review builds upon prior assessments while aiming 104 to have a higher degree of comprehensiveness than any previously published. To achieve this, 105 our search has been extended from global databases for influenza virological surveillance (e.g. 106 WHO-FluNet and GISAID) [Paget 2022], to include another surveillance database (GISHN), 107 biomedical literature databases (PubMed and EMBASE), as well as the webpages of national 108 surveillance systems around the world. 109

110

It is made available under a CC-BY-NC-ND 4.0 International license .

112 Methods

113 <u>Systematic literature review</u>

On March 20th, 2023, we searched PubMed and EMBASE using the following search 114 string: ((influenza OR flu) AND (Yamagata OR Victoria OR lineage OR Vic OR Yam)) OR 115 ("influenza b"). All articles published from January 1st, 2020 onwards were subjected to a multi-116 step selection process to evaluate their eligibility for inclusion in the literature review. The 117 selection procedure consisted of an initial screening-out step in which two investigators (SC and 118 119 BB) independently discarded irrelevant articles based on their title and abstract, and a second step in which all the articles retained after the first step by at least one of the two investigators 120 were read in full text in order to evaluate their eligibility. We did not place any language 121 122 restriction as long as an English title and abstract were available for the first step of the selection process. Finally, we included articles focusing on influenza in which the collection of respiratory 123 specimens for influenza testing extended from at least February 28th, 2020, and in which the 124 virus lineage was determined in all or a subset of the detected influenza B cases. We excluded 125 articles in which: (a) the data collection period was entirely prior to 2020 or was not specified; 126 (b) no respiratory specimens tested positive for influenza; (c) all influenza detections were due to 127 type A viruses, or the virus type was not determined; (d) none of influenza B detections was 128 tested to determine the virus lineage; or (e) there were no original data (e.g. commentaries, 129 130 editorials, or letters without data). Articles that were entirely based on data from the WHO-FluNet, the Global Initiative on Sharing All Influenza Data (GISAID), or the Global Influenza 131 Hospital Surveillance Network (GISHN) study were not considered, since an extensive search of 132 133 these databases was also conducted as part of the present study (see below). We applied no restrictions in terms of study design: therefore, studies as diverse as surveillance reports, 134

It is made available under a CC-BY-NC-ND 4.0 International license .

hospital-based clinical studies, vaccine-effectiveness studies, and phylogenetic analysis of
influenza isolates (e.g. to determine their genetic and antigenic characteristics) were all
considered as potentially eligible for inclusion as long as they matched the criteria listed above.

The data extracted from each eligible study included: study country, start and end of data collection, number of respiratory specimens that were collected and tested for influenza, number of those testing positive for influenza and specifically for type B influenza, and, among the type B influenza, the number of those that were characterized and the number that had a B/Yamagata lineage.

143

144 Influenza B/Yamagata viruses reported in the WHO-FluNet, GIHSN, and GISAID

The FluNet (https://www.who.int/tools/flunet) is a web-based database that is coordinated 145 by the WHO and is freely available to researchers. The FluNet database contains information on 146 the weekly number of laboratory-confirmed influenza detections that are uploaded from WHO 147 regional databases or directly entered by national influenza centres (NICs) and other influenza 148 reference laboratories from 194 countries and territories (in August 2023) participating in the 149 150 GISRS (Global Influenza Surveillance and Response System) initiative. Information on the influenza virus type is available for the vast majority of reported cases as well as the influenza A 151 virus subtype, while the proportion of influenza B cases for which the lineage is reported varies 152 considerably across countries and years [Zanobini 2022]. Influenza data from week 1 of 2020 153 onwards was downloaded from the FluNet on August 28th, 2023. The total number of influenza 154 B/Yamagata detections and the number per 100,000 tested specimens, total influenza cases, and 155 influenza B cases (overall and the subset of those that were characterized) were calculated for 156

It is made available under a CC-BY-NC-ND 4.0 International license .

each of the following five periods: 2020 weeks 1-17 (January-April), 2020 weeks 18-53 (MayDecember), 2021, 2022, and 2023 weeks 1-33. Moreover, we collected the names of the
countries in which influenza B/Yamagata detections occurred in each of these five periods.

160 The GIHSN (https://gihsn.org/) initiative was launched in 2012 through a partnership between industry, public health institutions, and sentinel hospitals in several countries around the 161 162 world. The overarching objective of GIHSN is to collect data on the epidemiology of severe influenza, defined as a laboratory-confirmed influenza infection resulting in hospitalization, and 163 provide annual estimates of the effectiveness of the influenza vaccine in preventing influenza-164 165 associated hospitalization. The GIHSN database was queried for severe influenza B/Yamagata cases reported from week 1 of 2020 to week 20 of 2023, with 21 countries contributing data on 166 influenza in at least one season during this period (Brazil, Canada, China, France, India, Ivory 167 Coast, Kenya, Lebanon, Mexico, Nepal, Pakistan, Peru, Romania, Russia, Senegal, Serbia, South 168 Africa, Spain, Turkey, Ukraine, and the USA). 169

170 GISAID (Global Initiative on Sharing All Influenza Data; https://gisaid.org/) is a publicly accessible repository established in 2008 to share viral genomic data for influenza (later 171 expanded to include SARS-CoV-2 and other pathogens). The GISAID database includes genetic 172 sequences for all influenza viruses as well as related epidemiological data, and access is provided 173 174 free-of-charge to users around the world in order to stimulate research and gain understanding on 175 how influenza viruses evolve over time and spread globally. As GISAID includes influenza virus sequences from other sequence databases, such as GenBank, these other databases were not 176 queried separately. The GISAID database was queried on 9 September 2023 for all B/Yamagata 177 178 and B/unknown-lineage labelled sequences with a collection date from March 1st, 2020 onwards. Sequences were analysed using GISAID and GenBank blast and phylogenetic analysis using 179

It is made available under a CC-BY-NC-ND 4.0 International license .

180 MEGA version 7.0.21 taking into account sequences of all available segments, and Nextclade

version 2.14.1 (<u>https://clades.nextstrain.org/</u>) for hemagglutinin segment assessment.

182

183 <u>Review of national respiratory viruses surveillance systems 'webpages</u>

184 During May and June 2023, we searched the web pages of influenza and respiratory 185 viruses surveillance systems of the following countries: England, France, Germany, Italy, 186 Netherlands, Portugal, Russia and Spain (Europe); Argentina, Brazil, Canada, Mexico and USA 187 (Americas); China, Hong Kong, Israel, Japan and Turkey (Asia); Australia and New Zealand (Oceania); and South Africa (Africa). These countries were selected due to their geographical 188 189 representativeness and availability of web-based surveillance reports. Extracted information was 190 the number of respiratory specimens tested for influenza, as well as the number of influenza detections, overall and by virus type (A and B); if available for influenza B viruses, the virus 191 lineage (Victoria, Yamagata, and not characterized) was also recorded. Moreover, we retrieved 192 the available information on the main features of the surveillance system and the duration of the 193 surveillance period (i.e. whether year-round or if limited to the usual epidemic period). 194

It is made available under a CC-BY-NC-ND 4.0 International license .

196 **Results**

197 *Literature review*

The literature search returned 2.147 entries in PubMed and 3.983 in EMBASE. The non-198 duplicate articles were 4,333, of which 3,746 were discarded based on the title and abstract 199 (Figure 1). Of the remaining 587 articles, 547 were discarded for not matching the inclusion 200 criteria (of these, 62 were not further considered since no reported influenza cases were type B), 201 7 for being based on the WHO FluNet and/or GISAID database, 3 for being previous reports 202 203 from the GIHSN, and 4 because of overlap with more recent and/or larger articles based on the same data sources. A total of 26 articles were included in the systematic review: their main 204 characteristics are reported in Table 1 [Soldevila 2022, Murillo-Zamora 2021, Korsun 2021, 205 206 Panatto 2021, Pablo-Marcos 2020, Miron 2021, Hu 2021, Omer 2022, Olson 2022, Auvinen 2022, Kuzmanovska 2021, Wagatsuma 2022, Heinzinger 2021, Rios-Silva 2022, 207 Suntronwong 2021, da Costa 2022, Melidou 2020, Huang 2022, O'Neill 2022, Kolosova 208 2022, Peck 2023, Chon 2023, Merced-Morales 2022, Melidou 2022, Sominina 2022, Song 209 2022]. Europe was the most represented area (12 articles, of which 2 reported findings from 210 multiple countries in the WHO European Region), followed by Asia (n=6), North America (n=5), 211 and Oceania and South America (n=1 each). In addition, the paper by O'Neill et al. reported 212 influenza positive samples coming from fourteen countries in Oceania, Asia, and Africa during 213 214 2020-2021, that were subtyped at the WHO CCRRI (Collaborating Centre for Reference and Research for Influenza) in Melbourne [O'Neill 2022]. 215

In **Table 1**, studies were ordered according to the start and the end of the observation period. In two articles, data collection began several years before the start of the COVID-19 pandemic [**Soldevila 2022**, **Murillo-Zamora 2021**]: B/Yamagata viruses accounted for a large

It is made available under a CC-BY-NC-ND 4.0 International license .

219 proportion of all characterized influenza B-positive specimens, but since data stratified by year were not available, it was not possible to assess how many of them were seen after March 1st, 220 2020. Ten studies reported data for the Northern hemisphere 2019-2020 influenza season: in only 221 two of these there were B/Yamagata detections, which represented a very minor percentage of all 222 influenza-positive specimens (1 out of 1,683 in Panatto et al, Italy [Panatto 2021], and 6 out of 223 224 28,176 in Hu et al., USA [Hu 2021]). In two more studies (Heinzinger et al., Germany, and Ríos-Silva et al., Mexico), data collection started in 2019 and ended in 2021 or, respectively, 2022 225 [Heinzinger 2021, Rios-Silva 2021]: in both studies, there were no B/Yamagata detections after 226 227 the 2019-2020 season.

Three studies included data that were collected entirely in 2020: Melidou et al. analyzed 228 European surveillance data from TESSy during the weeks 1-20 of 2020 and reported a single 229 influenza B/Yamagata case (out of 1,691 influenza detections overall, of which 397 were 230 influenza B) [Melidou 2020], while in the other two studies, conducted in Thailand and Brazil, 231 the observation period was January-March 2020 and there were no reported B/Yamagata 232 detections [Suntronwong 2021, da Costa 2022]. In nine more studies, the observation period 233 started in 2020 or 2021, and ended in 2021 or 2022. In China, the proportion of influenza-234 235 positive specimens reported to the Chinese National Influenza Surveillance Systems that were caused by B/Yamagata lineage viruses was 0.22% in 2020 and 0.07% in 2021 [Huang 2022]. 236 237 The remaining studies whose observation period started in 2020 or 2021 and ended in 2021 or 238 2022 reported no or a very limited number of influenza B/Yamagata detections, which after sequencing were found to be partly linked (in Melidou et al. 2022 and Merced-Morales et al. 239 2022 [Melidou 2022, Merced-Morales 2022]) to vaccination with LAIV. 240

It is made available under a CC-BY-NC-ND 4.0 International license .

In summary, we reviewed studies published up to March 2023 and whose observation period extended up to 2022, and found that B/Yamagata detections were reported only in a very few countries globally (and accounting for a very minor proportion of all influenza B cases) after the first few months of 2020.

245

246 <u>WHO-FluNet, GIHSN, and GISAID</u>

On August 28th, 2023, we downloaded data from the WHO-FluNet for the period from 247 248 week 1 of 2020 to week 33 of 2023. The database contained around 31.93 million respiratory specimens and 1,998,172 million influenza detections, of which 379,699 (19.0%) were influenza 249 B viruses. Of these, 272,236 (71.7%) were not characterized, 107,048 (28.2%) were B/Victoria 250 251 lineage, and 415 (0.1%) were B/Yamagata lineage. The average number of influenza B/Yamagata detections per 100,000 processed specimens dropped from 14.9 in the weeks 1-17 of 2020 to 252 below 0.10 in 2022 and 2023 (Table 2). Influenza B/Yamagata accounted for a significantly 253 greater proportion of detections during the weeks 18-52 of 2020 compared to the earlier weeks in 254 the same year. This was followed by a major drop in the frequency of influenza B/Yamagata 255 detections in 2021 and 2022 (Table 2): the number of influenza B/Yamagata detections dropped 256 from 364 in 2020 to 45 in 2021 and three in 2022 (two from Germany and one from North 257 Korea). In the first 33 weeks of 2023, there were 6 B/Yamagata detections globally, of which five 258 259 were from Cameroon and one from Cuba: this represented a slight increase compared to 2022 but remained well below the numbers in 2020 and 2021 (Table 2). In summary, the rate of 260 B/Yamagata detections entered in the WHO-FluNet database dropped significantly worldwide 261 after 2020, both in absolute terms and as a percentage of the total number of influenza and 262 263 influenza type B detections (Table 2).

The number of influenza detections within the *GIHSN* is reported in **Table 3**. Out of a total of 8,590 influenza detections reported between January 2020 and week 27 of 2023, 2,055 (23.9%) were influenza B. Of the 978 influenza B viruses that were characterized, seven (0.7%) were B/Yamagata, all detected in 2020 (two in France, two in Mexico, one in India and one in Russia in the first three months of the year, and again one in India in week 51). No B/Yamagata influenza detections were reported from 2021 onwards.

On September 9th, the GISAID database was queried for all influenza B/Yamagata and 270 B/unknown-lineage sequences with collection date from March 1st, 2020, onwards. The set of 271 272 B/Yamagata sequences included a total of 20 non-duplicate viruses. Collection dates were in March 2020 (n=14), November 2021 (n=4, all from Kenya), June 2022 (n=1, from Greece) and 273 274 March 2023 (n=1, from the UK). Of these, two (from Japan, 2020, and Greece, 2022) had an HA genome segment identical to that of a B/Yamagata-like vaccine strain, suggesting both were 275 vaccine-derived viruses. Of the five viruses from 2021 and 2023 only the PA (n=3) or MP (n=2) 276 segment was available. For three of the four viruses from Kenya (2021), the limited available 277 information made it difficult to determine whether they were from wildtype circulating 278 B/Yamagata lineage viruses. For the remaining virus from Kenya and the virus from UK, the MP 279 280 segment matched with highest rank with B/Victoria lineage viruses, suggesting that these detections were incorrectly labelled B/Yamagata. The B/unknown-lineage dataset included 128 281 282 unique viruses. The blast and phylogenetic analysis revealed that the majority (n=111) of these 283 were wildtype B/Victoria and 7 were derived from the study published in 2023 by Aslam et al. on historic B viruses for influenza vaccine virus construction [Aslam 2023]. Of the remaining 10 284 viruses, two collected in the USA in 2021 and one from South Korea with data collection in 2020 285 were highly likely LAIV derived. Finally, seven waste water specimens collected in March 2020 286

It is made available under a CC-BY-NC-ND 4.0 International license .

in New York had partial PB1 sequences similar to 2007/2008 B/Yamagata lineage viruses, however, no sequences of other segments were available for definitive assessment. In conclusion, no sequences of wildtype viruses of the B/Yamagata lineage with a collection date after March 2020 have been uploaded to GISAID and GenBank, including the viruses reported as B/Yamagata lineage to FluNet and GIHSN after March 2020 (of note, therefore, for these later viruses there was no objective assessment possible whether these viruses were wildtype or vaccine-derived).

294

295 <u>Review of national respiratory viruses' surveillance systems' webpages</u>

The number of influenza B/Yamagata detections reported by country and period is shown in **Table 4**, alongside with details of the surveillance system in which each case was observed and overall number of influenza cases reported. After week 35 of 2020, 11 B/Yamagata detections were reported: one in Australia (week 37-38 of 2020), nine in the USA (weeks 44-49 of 2021) and an additional case in the USA in week 46 of 2021. No B/Yamagata were reported during 2022 and 2023 until the time of our search in June 2023.

302

To summarize the findings, we present the countries in which the last B/Yamagata detections (from any of the sources that we explored) was reported in 2023 (n = 2), 2022 (n = 3), or 2021 (n=9) in **Figure 2**. In all the remaining word countries, there we no B/Yamagata detections after 2020.

307

It is made available under a CC-BY-NC-ND 4.0 International license .

309 **Discussion**

310 The early claims that the influenza B/Yamagata lineage may have gone extinct in the aftermath of the COVID-19 pandemic quickly raised the attention of policymakers (e.g. WHO) 311 312 and vaccine manufacturers, as well as epidemiologists and researchers, due to the important implications this would have on the formulation and development of both inactivated and 313 314 attenuated influenza vaccines. Given the enormous public health relevance and the need for solid 315 and constantly updated epidemiological data, we undertook an extensive review of the available 316 evidence on the topic, which covered multiple complementary sources of information and was 317 therefore intended to be as comprehensive as possible.

Considering all of the collected information, the different sources investigated are 318 319 concordant in showing that the number of influenza B/Yamagata viruses detections has declined considerably and progressively over the last 3.5 years (i.e. from the onset of the COVID-19 320 pandemic) compared with the pre-pandemic period, both in absolute terms (i.e. number of 321 detections) and in terms of the positivity rate or as a fraction of the total number of influenza B 322 detections. After the 2009 H1N1 influenza pandemic, influenza B viruses had resumed 323 circulation causing about a quarter of all influenza cases globally on average [Zanobini 2022]. 324 Following the major B/Yamagata outbreak that started in 2017 and involved large parts of the 325 326 world, however, the circulation of B/Yamagata viruses had fallen considerably (they accounted 327 for only one twentieth of all influenza B cases in 2018-2019 [Zanobini 2022]): this may help explain (together with the lack of known zoonotic or environmental reservoirs) why it is the only 328 respiratory virus that has been pushed towards extinction by the emergence of SARS-CoV-2. 329 330 Indeed, only a few detected B/Yamagata cases were reported in 2022-2023, but since the different world areas are unevenly covered by respiratory virus surveillance systems, some 331

It is made available under a CC-BY-NC-ND 4.0 International license .

332 caution is warranted regarding whether the B/Yamagata lineage is actually extinct. However, the current epidemiological situation, with the rapid global disappearance (and potential extinction) 333 of an influenza B virus lineage, is unprecedented since influenza B viruses split into two lineages 334 in the early 1980s. In the 1990s, the B/Victoria lineage had practically disappeared from most 335 world regions (including Europe and North America), but viral circulation endured in populous 336 337 East Asia, so it was plausible to expect that it would re-emerge globally at some point (as it happened in 2001-2002) [Xu 2015, Ikonen 2005]. Today, the protracted and nearly undetectable 338 viral circulation of B/Yamagata influenza viruses (including in East Asia) makes it much more 339 340 likely that we are on the verge of B/Yamagata extinction, if it hasn't already occurred. In this context, it is critical that B/Yamagata detections captured by surveillance systems or studies 341 around the world within the context of research projects are properly investigated to determine 342 whether B/Yamagata cases are wild- or vaccine-derived virus detections, and that a much larger 343 proportion of influenza B detections are tested to determine their lineage. Vaccine-derived 344 345 detections can mostly be linked to sampling LAIV vaccinated individuals and indeed, several B/Yamagata viruses whose sequences are uploaded in GISAID appeared to be vaccine-derived. It 346 is therefore important sequencing of influenza B viruses is encouraged and supported and that 347 348 procedures are put in place to assess the true circulation of the wild-type B/Yamagata virus, with detailed virological (sequence confirmation) and epidemiological (i.e. vaccination status, timing 349 350 of vaccination and vaccine type) data being collected and shared (e.g. with the WHO and the 351 WHO Collaborating Centres).

Aside from the question of whether B/Yamagata viruses have or have not already become extinct, the current epidemiological situation calls for a rapid response in terms of influenza prevention practices. In particular, a decision needs to be made regarding as to whether QIVs

It is made available under a CC-BY-NC-ND 4.0 International license .

355 should be changed to TIVs and, if so, whether this change should be applied simultaneously to both egg-based vaccines and LAIVs. Any decision in this regard would have regulatory and 356 manufacturing implications which would require different timescales to be implemented. 357 Importantly from a public health perspective, it is critical that countries are not confronted with a 358 situation where there are influenza vaccines shortages, thus these decisions would need to be 359 360 taken with care and in a coordinated manner. Also, concerns exist about how the change from QIV to TIV should be communicated, as this could be confusing for the general public and have 361 a negative impact on national influenza vaccination campaigns. Perhaps more theoretically (as 362 363 implementation would be less immediate), the option of maintaining a quadrivalent vaccine by removing the B/Yamagata virus strain and replacing it with another strain (e.g. two H3N2 364 strains) would be worth discussing. Of note, there are other issues that are important beyond 365 those concerning vaccine formulation and development. In particular, if B/Yamagata viruses are 366 considered extinct, the question arises as to whether influenza laboratories around the world 367 368 should change the security level with which they are allowed to handle B/Yamagata viruses, due to the potential risks associated with the escape of an extinct influenza virus. 369

A few aspects relating to the sources of information that we researched deserve comment. 370 371 The WHO-FluNet database is dynamic in that the data it contains can change over time. For example, a NIC or reference laboratory in a given country may need to make corrections to data 372 373 entered in previous weeks. As far as our current research question is concerned, it is worth noting 374 that the WHO-FluNet database does not presently have an option to report vaccine-derived 375 detections separately. We are aware that WHO proactively investigates all reports of B/Yamagata entered into their global surveillance databases and these are sometimes removed at a later stage 376 when laboratory analyses reveal that they are vaccine-derived. In preparing this article, the 2020-377

It is made available under a CC-BY-NC-ND 4.0 International license .

2023 data from the WHO-FluNet database were downloaded twice, on May 19th and then again 378 on August 28th 2023. In this short time period, the number of reported B/Yamagata influenza 379 cases decreased from 45 to 42 for the year 2021, and from 8 to 3 for the year 2022. Hence, 380 although the number of B/Yamagata detections in 2023, as shown in Table 2, slightly exceeded 381 the number in 2022 (6 vs. 3), this might be an overestimate compared to reality (and the same 382 considerations may apply to the GISAID database). A further limitation is the under-383 representation of tropical countries, particularly in populous South-East Asia and Africa, in data 384 gathered from the review of scientific literature and webpages of respiratory viruses' surveillance 385 386 systems. This is important as we have previously shown that influenza B tended to circulate more intensely in the tropics than in the temperate countries before the COVID-19 pandemic 387 [Caini 2019]. While a main strength of our data review is the systematic and comprehensive 388 nature of the exercise, one should recognise the limitations and shortcomings of the information 389 sources that we researched in order to be able to critically appraise the whole body of evidence 390 currently available on this topic. 391

We have described the current epidemiological situation regarding B/Yamagata lineage 392 viruses, and outlined its most important public health implications, particularly with regard to the 393 394 composition of influenza vaccines. A further, and currently overlooked source of uncertainty with implications for immunization campaigns, relates to the timing of influenza epidemics in 395 the coming years [Caini 2018]. Right now, there is in fact no guarantee that the pre-pandemic 396 397 timing will be restored, or if instead, the co-circulation of SARS-CoV-2 will cause influenza epidemics to be shifted by a few weeks earlier or later due to viral interference [Fage 2022, Piret 398 **2022**], which might in turn entail the need to accommodate the timing of vaccine strains 399 selection, manufacturing, and deployment. Furthermore, it is currently difficult to make 400

It is made available under a CC-BY-NC-ND 4.0 International license .

401 predictions about the impact that the disappearance of B/Yamagata viruses will have on the circulation of other influenza viruses. B/Yamagata viruses tended to infect adults and the elderly 402 more often than those of the B/Victoria lineage, which are to a much larger extent limited to 403 children and adolescents [Caini 2019]. If B/Yamagata viruses actually became extinct, the age 404 distribution of influenza B cases might shift towards younger ages, thus resulting in a lower 405 406 disease burden than in the pre-COVID-19 era. However, this is currently nothing more than a 407 plausible hypothesis that only time will allow one to confirm or refute. These many uncertainties imply that the role of epidemiological and virological monitoring of influenza viruses, SARS-408 409 CoV-2, and the other respiratory viruses in protecting the health of populations is presently more important than ever and will remain so for many years to come. In conclusion, international and 410 national public health authorities (both public health institutes and medical regulatory 411 authorities) are confronted with an unprecedented situation with the rapid disappearance and 412 potential extinction of the influenza B/Yamagata virus (a development they have not experienced 413 414 in the last 30 years) and need to take important decisions regarding influenza vaccines and the B/Yamagata virus, and we believe this review will contribute to this decision-making process. 415

416

It is made available under a CC-BY-NC-ND 4.0 International license .

418 Acknowledgments

- 419 We would like to thank investigators at all sites participating to the Global Influenza Hospital
- 420 Surveillance Network (GIHSN).

421

422 Funding statement

- 423 Saverio Caini, Adam Meijer, Laetitia Henaff and Malaika Zounon received no specific finding
- 424 for this work. John Paget, Marco Del Riccio and Bronke Boudewijns were funded via a research
- 425 grant from Sanofi to NIVEL (FluCov project). Marta Nunes was funded via a research grant

426 from Sanofi to CERP.

It is made available under a CC-BY-NC-ND 4.0 International license .

428

429 **References**

- 430 1. Dhanasekaran V, Sullivan S, Edwards KM, Xie R, Khvorov A, Valkenburg SA, Cowling
- 431 BJ, Barr IG. Human seasonal influenza under COVID-19 and the potential consequences
- 432 of influenza lineage elimination. Nat Commun. 2022 Mar 31;13(1):1721. doi:
 433 10.1038/s41467-022-29402-5.
- Olsen SJ, Azziz-Baumgartner E, Budd AP, Brammer L, Sullivan S, Pineda RF, Cohen C,
 Fry AM. Decreased Influenza Activity During the COVID-19 Pandemic United States,
 Australia, Chile, and South Africa, 2020. MMWR Morb Mortal Wkly Rep. 2020 Sep
 18;69(37):1305-1309. doi: 10.15585/mmwr.mm6937a6.
- Merced-Morales A, Daly P, Abd Elal AI, Ajayi N, Annan E, Budd A, Barnes J, Colon A,
 Cummings CN, Iuliano AD, DaSilva J, Dempster N, Garg S, Gubareva L, Hawkins D,
 Howa A, Huang S, Kirby M, Kniss K, Kondor R, Liddell J, Moon S, Nguyen HT,
 O'Halloran A, Smith C, Stark T, Tastad K, Ujamaa D, Wentworth DE, Fry AM, Dugan
 VG, Brammer L. Influenza Activity and Composition of the 2022-23 Influenza Vaccine United States, 2021-22 Season. MMWR Morb Mortal Wkly Rep. 2022 Jul
 22;71(29):913-919. doi: 10.15585/mmwr.mm7129a1.
- 4. Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G, Palmieri A,
 Affanni P, Camilloni B, Chironna M, D'Agaro P, Giannecchini S, Pariani E, Serra C,
 Rizzo C, Bella A, Donatelli I, Castrucci MR; Italian Influenza Laboratory Network. Cocirculation of the two influenza B lineages during 13 consecutive influenza surveillance
 seasons in Italy, 2004-2017. BMC Infect Dis. 2019 Nov 21;19(1):990. doi:
 10.1186/s12879-019-4621-z.

It is made available under a CC-BY-NC-ND 4.0 International license .

451	5.	Zanobini P. Bonaccorsi G. Lorini C. Haag M. McGovern I. Paget J. Caini S. Global
452		patterns of seasonal influenza activity, duration of activity and virus (sub)type circulation
453		from 2010 to 2020. Influenza Other Respir Viruses. 2022 Jul;16(4):696-706. doi:
454		10.1111/irv.12969.
455	6.	Koutsakos M, Wheatley AK, Laurie K, Kent SJ, Rockman S. Influenza lineage extinction
456		during the COVID-19 pandemic? Nat Rev Microbiol. 2021 Dec;19(12):741-742. doi:
457		10.1038/s41579-021-00642-4.
458	7.	Paget J, Caini S, Del Riccio M, van Waarden W, Meijer A. Has influenza B/Yamagata
459		become extinct and what implications might this have for quadrivalent influenza
460		vaccines? Euro Surveill. 2022 Sep;27(39):2200753. doi: 10.2807/1560-
461		7917.ES.2022.27.39.2200753.
462	8.	Xu C, Chan KH, Tsang TK, Fang VJ, Fung RO, Ip DK, Cauchemez S, Leung GM, Peiris
463		JS, Cowling BJ. Comparative Epidemiology of Influenza B Yamagata- and Victoria-
464		Lineage Viruses in Households. Am J Epidemiol. 2015 Oct 15;182(8):705-13. doi:
465		10.1093/aje/kwv110.
466	9.	Dudas G, Bedford T, Lycett S, Rambaut A. Reassortment between influenza B lineages
467		and the emergence of a coadapted PB1-PB2-HA gene complex. Mol Biol Evol. 2015

468 Jan;32(1):162-72. doi: 10.1093/molbev/msu287.

469 10. Vesikari T, Karvonen A, Korhonen T, Edelman K, Vainionpää R, Salmi A, Saville MK,

470 Cho I, Razmpour A, Rappaport R, O'Neill R, Georgiu A, Gruber W, Mendelman PM,

- 471 Forrest B; CAIV-T Transmission Study Group. A randomized, double-blind study of the
- 472 safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza

473	virus	vaccine.	Pediatr	Infect	Dis	J.	2006	Jul;25(7):590-5.	doi:
474	10.109	7/01.inf.000	0220229.51	531.47.					

- 475 11. Soldevila N, Basile L, Martínez A, Torner N, Marcos MÁ, Mosquera MDM, Antón A,
 476 Andrés C, Rius C, Pumarola T, Domínguez Á; the PIDIRAC Surveillance of Hospitalized
 477 Cases of Severe Influenza in Catalonia Working Group. Surveillance of influenza B
 478 severe hospitalized cases during 10 seasons in Catalonia: Does the lineage make a
 479 difference? J Med Virol. 2022 Sep;94(9):4417-4424. doi: 10.1002/jmv.27876.
- 12. Murillo-Zamora E, Trujillo X, Huerta M, Ríos-Silva M, Guzmán-Esquivel J, Benites-480 Godínez V, Mendoza-Cano O. Survival in influenza virus-related pneumonia by viral 481 subtype: 2016-2020. 2021 Nov;112:288-293. doi: 482 Int J Infect Dis. 10.1016/j.ijid.2021.09.037. 483
- 484 13. Korsun N, Trifonova I, Voleva S, Grigorova I, Angelova S. Genetic characterisation of
 485 the influenza viruses circulating in Bulgaria during the 2019-2020 winter season. Virus
 486 Genes. 2021 Oct;57(5):401-412. doi: 10.1007/s11262-021-01853-w.
- 14. Panatto D, Orsi A, Pennati BM, Lai PL, Mosca S, Bruzzone B, Caligiuri P, Napoli C,
 Bertamino E, Orsi GB, Manini I, Loconsole D, Centrone F, Pandolfi E, Ciofi Degli Atti
 ML, Concato C, Linardos G, Onetti Muda A, Raponi M, Piccioni L, Rizzo C, Chironna
 M, Icardi G. No evidence of SARS-CoV-2 in hospitalized patients with severe acute
 respiratory syndrome in five Italian hospitals from 1st November 2019 to 29th February
- 492 2020. PLoS One. 2021 Dec 7;16(12):e0260947. doi: 10.1371/journal.pone.0260947.
- 493 15. Pablo-Marcos D, Rodríguez-Fernández A, Gozalo M, Agüero J, Arnaiz de Las Revillas F,
- 494 Calvo J. Descripción de la epidemia estacional por Gripe B en Cantabria durante los
 495 inicios de la pandemia por SARS-CoV-2 [Description of Influenza B in seasonal

496	epidemic in Cantabria during the beginning of the pandemia due to SARS-CoV-2]. Rev
497	Esp Quimioter. 2020 Dec;33(6):444-447. Spanish. doi: 10.37201/req/077.2020.
498	16. Miron VD, Bănică L, Săndulescu O, Paraschiv S, Surleac M, Florea D, Vlaicu O, Milu P,
499	Streinu-Cercel A, Bilașco A, Oțelea D, Pițigoi D, Streinu-Cercel A, Drăgănescu AC.
500	Clinical and molecular epidemiology of influenza viruses from Romanian patients
501	hospitalized during the 2019/20 season. PLoS One. 2021 Nov 12;16(11):e0258798. doi:
502	10.1371/journal.pone.0258798.
503	17. Hu W, Gruner WE, DeMarcus LS, Thervil JW, Kwaah B, Fries AC, Sjoberg PA, Robbins
504	AS. Influenza Surveillance Trends and Influenza Vaccine Effectiveness Among
505	Department of Defense Beneficiaries During the 2019-2020 Influenza Season. MSMR.
506	2021 Mar;28(3):2-8.
507	18. Omer I, Rosenberg A, Sefty H, Pando R, Mandelboim M, Mendelson E, Keinan-Boker L,
508	Glatman-Freedman A; Israel Influenza Surveillance Network (IISN). Lineage-matched
509	versus mismatched influenza B vaccine effectiveness following seasons of marginal
510	influenza B circulation. Vaccine. 2022 Feb 7;40(6):880-885. doi:
511	10.1016/j.vaccine.2021.12.056.
512	19. Olson SM, Newhams MM, Halasa NB, Feldstein LR, Novak T, Weiss SL, Coates BM,
513	Schuster JE, Schwarz AJ, Maddux AB, Hall MW, Nofziger RA, Flori HR, Gertz SJ, Kong
514	M, Sanders RC, Irby K, Hume JR, Cullimore ML, Shein SL, Thomas NJ, Stewart LS,
515	Barnes JR, Patel MM, Randolph AG; Pediatric Intensive Care Influenza Investigators.
516	Vaccine Effectiveness Against Life-Threatening Influenza Illness in US Children. Clin
517	Infect Dis. 2022 Aug 25;75(2):230-238. doi: 10.1093/cid/ciab931.

- 20. Auvinen R, Syrjänen R, Ollgren J, Nohynek H, Skogberg K. Clinical characteristics and
 population-based attack rates of respiratory syncytial virus versus influenza
 hospitalizations among adults-An observational study. Influenza Other Respir Viruses.
 2022 Mar;16(2):276-288. doi: 10.1111/irv.12914.
- 522 21. Kuzmanovska M, Boshevska G, Janchevska E, Buzharova T, Simova M, Peshnacka A,
- 523 Nikolovska G, Kochinski D, Ilioska RS, Stavridis K, Mikikj V, Kuzmanovska G, Memeti
- 524 S, Gjorgoski I. A Comprehensive Molecular and Epidemiological Characterization of
- 525Influenza Viruses Circulating 2016-2020 in North Macedonia. Front Microbiol. 2021 Oct
- 526 21;12:713408. doi: 10.3389/fmicb.2021.713408.
- 527 22. Wagatsuma K, Saito R, Chon I, Phyu WW, Fujio K, Kawashima T, Sato I, Saito T,
 528 Minato M, Kodo N, Suzuki E, Ono Y, Masaki H, Shirahige Y, Kitano A, Hamabata H,
 529 Yuyang S, Jiaming L, Watanabe H. Duration of fever and symptoms in influenza-infected
 530 children treated with baloxavir marboxil during the 2019-2020 season in Japan and
 531 detection of influenza virus with the PA E23K substitution. Antiviral Res. 2022
 532 May;201:105310. doi: 10.1016/j.antiviral.2022.105310.
- 23. Heinzinger S, Eberle U, Angermeier H, Flechsler J, Konrad R, Dangel A, Berger C,
 Sprenger A, Hepner S, Biere B, Liebl B, Ackermann N, Sing A. Reciprocal circulation
 pattern of SARS-CoV-2 and influenza viruses during the influenza seasons 2019/2020
 and 2020/2021 in the Bavarian Influenza Sentinel (Germany). Epidemiol Infect. 2021 Oct
 26;149:e226. doi: 10.1017/S0950268821002296. Erratum in: Epidemiol Infect. 2022 Feb
 11;150:e24.
- 539 24. Ríos-Silva M, Trujillo X, Huerta M, Benites-Godínez V, Guzmán-Esquivel J, Bricio540 Barrios JA, Mendoza-Cano O, Lugo-Radillo A, Murillo-Zamora E. Reemerging

- Influenza Virus Infections during the Dominance of the Omicron SARS-CoV-2 Variant in
 Mexico. Pathogens. 2022 Oct 13;11(10):1181. doi: 10.3390/pathogens11101181.
- 543 25. Suntronwong N, Klinfueng S, Korkong S, Vichaiwattana P, Thongmee T, Vongpunsawad
- 544 S, Poovorawan Y. Characterizing genetic and antigenic divergence from vaccine strain of
- 545 influenza A and B viruses circulating in Thailand, 2017-2020. Sci Rep. 2021 Jan
- 546 12;11(1):735. doi: 10.1038/s41598-020-80895-w.
- 26. Costa JCD, Siqueira MM, Brown D, Lopes JO, Costa BCD, Gama EL, Aguiar-Oliveira
 ML. Vaccine Mismatches, Viral Circulation, and Clinical Severity Patterns of Influenza B
 Victoria and Yamagata Infections in Brazil over the Decade 2010-2020: A Statistical and
 Phylogeny-Trait Analyses. Viruses. 2022 Jul 5;14(7):1477. doi: 10.3390/v14071477.
- Filylogeny-frait Analyses. viruses. 2022 Jul 5,14(7).1477. doi: 10.5590/v140/1477.
- 27. Melidou A, Pereyaslov D, Hungnes O, Prosenc K, Alm E, Adlhoch C, Fielding J,
 Sneiderman M, Martinuka O, Celentano LP, Pebody R; WHO European Region influenza
 surveillance network; WHO European Region Influenza Surveillance Network author
 list. Virological surveillance of influenza viruses in the WHO European Region in
 2019/20 impact of the COVID-19 pandemic. Euro Surveill. 2020 Nov;25(46):2001822.
 doi: 10.2807/1560-7917.ES.2020.25.46.2001822.
- 28. Huang WJ, Cheng YH, Tan MJ, Liu J, Li XY, Zeng XX, Tang J, Wei HJ, Chen T, Yang L,
 Xie YR, Yang JY, Xiao N, Wang DY. Epidemiological and virological surveillance of
 influenza viruses in China during 2020-2021. Infect Dis Poverty. 2022 Jun 29;11(1):74.
- 560 doi: 10.1186/s40249-022-01002-x
- 561 29. O'Neill G, Aziz A, Kuba M, Brown SK, Lau H, Soppe S, Baz M, Peck H, Deng YM,
 562 Subbarao K, Barr IG Report on influenza viruses received and tested by the Melbourne

563	WHO Collaborating Centre for Reference and Research on Influenza during 2020-2021.
564	Commun Dis Intell (2018). 2022 Sep 26;46. doi: 10.33321/cdi.2022.46.63.
565	30. Kolosova NP, Ilyicheva TN, Svyatchenko SV, Danilenko AV, Onkhonova GS, Ivanova
566	KI, Susloparov IM, Ryzhikov AB. Initial and severe cases of influenza in 2020-2022 and
567	population immunity prior to epidemic season. Medical Immunology (Russia).
568	2022;24(6):1219-1226. Russian. doi: 10.15789/1563-0625-IAS-2513.
569	31. Peck H, Anbumurali N, McMahon K, Freeman K, Aziz A, Gillespie L, Yang B, Moselen
570	J, Deng YM, Cowling BJ, Barr IG, Subbarao K, Sullivan SG. Detection of Influenza in
571	Managed Quarantine in Australia and the Estimated Risk of Importation. Clin Infect Dis.
572	2023 Feb 8;76(3):e1328-e1334. doi: 10.1093/cid/ciac648.
573	32. Chon I, Saito R, Kyaw Y, Aye MM, Setk S, Phyu WW, Wagatsuma K, Li J, Sun Y,
574	Otoguro T, Win SMK, Yoshioka S, Win NC, Ja LD, Tin HH, Watanabe H. Whole-
575	Genome Analysis of Influenza A(H3N2) and B/Victoria Viruses Detected in Myanmar
576	during the COVID-19 Pandemic in 2021. Viruses. 2023 Feb 20;15(2):583. doi:
577	10.3390/v15020583.
578	33. Melidou A, Ködmön C, Nahapetyan K, Kraus A, Alm E, Adlhoch C, Mooks P, Dave N,
579	Carvalho C, Meslé MM, Daniels R, Pebody R; Members of the WHO European Region
580	influenza surveillance network; Members of the WHO European Region influenza
581	surveillance network that contributed virus characterisation data. Influenza returns with a
582	season dominated by clade 3C.2a1b.2a.2 A(H3N2) viruses, WHO European Region,
583	2021/22. Euro Surveill. 2022 Apr;27(15):2200255. doi: 10.2807/1560-
584	7917.ES.2022.27.15.2200255.

- 34. Sominina A, Danilenko D, Komissarov A, Karpova L, Pisareva M, Fadeev A,
 Konovalova N, Eropkin M, Stolyarov K, Shtro A, Burtseva E, Lioznov D. Resurgence of
 Influenza Circulation in the Russian Federation during the Delta and Omicron COVID-19
 Era. Viruses. 2022 Aug 29;14(9):1909. doi: 10.3390/v14091909.
 Song SX, Sun L, He YJ, Wu JL, Sun WK, Zhang S, Li Z, Kou ZQ, Liu T. [Analysis of
 the epidemiological characteristics and genetic characteristics of influenza in the
 surveillance-year of 2021 to 2022 in Shandong Province, China]. Zhonghua Yu Fang Yi
- 592 Xue Za Zhi. 2022 Nov 6;56(11):1554-1559. Chinese. doi: 10.3760/cma.j.cn112150593 20220812-00807.
- 36. Aslam S, Rajendran M, Kriti D, Kurland A, Johnson J, van Bakel H, Krammer F, GarcíaSastre A, Ayllon J. Generation of a high yield vaccine backbone for influenza B virus in
 embryonated chicken eggs. NPJ Vaccines. 2023 Feb 10;8(1):12. doi: 10.1038/s41541023-00603-3.
- 37. Xu C, Chan KH, Tsang TK, Fang VJ, Fung RO, Ip DK, Cauchemez S, Leung GM, Peiris
 JS, Cowling BJ. Comparative Epidemiology of Influenza B Yamagata- and VictoriaLineage Viruses in Households. Am J Epidemiol. 2015 Oct 15;182(8):705-13. doi:
 10.1093/aje/kwv110.
- 38. Ikonen N, Pyhälä R, Axelin T, Kleemola M, Korpela H. Reappearance of influenza
 B/Victoria/2/87-lineage viruses: epidemic activity, genetic diversity and vaccination
 efficacy in the Finnish Defence Forces. Epidemiol Infect. 2005 Apr;133(2):263-71. doi:
 10.1017/s0950268804003462.
- 39. Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, Ferreira de
 Almeida WA, Njouom R, Fasce RA, Bustos P, Feng L, Peng Z, Araya JL, Bruno A, de

It is made available under a CC-BY-NC-ND 4.0 International license .

608	Mora D, Barahona de Gámez MJ, Pebody R, Zambon M, Higueros R, Rivera R, Kosasih
609	H, Castrucci MR, Bella A, Kadjo HA, Daouda C, Makusheva A, Bessonova O, Chaves
610	SS, Emukule GO, Heraud JM, Razanajatovo NH, Barakat A, El Falaki F, Meijer A,
611	Donker GA, Huang QS, Wood T, Balmaseda A, Palekar R, Arévalo BM, Rodrigues AP,
612	Guiomar R, Lee VJM, Ang LW, Cohen C, Treurnicht F, Mironenko A, Holubka O, Bresee
613	J, Brammer L, Le MTQ, Hoang PVM, El Guerche-Séblain C, Paget J; Global Influenza B
614	Study team. The epidemiological signature of influenza B virus and its B/Victoria and
615	B/Yamagata lineages in the 21st century. PLoS One. 2019 Sep 12;14(9):e0222381. doi:
616	10.1371/journal.pone.0222381.
617	40. Caini S, Schellevis F, El-Guerche Séblain C, Paget J. Important changes in the timing of
618	influenza epidemics in the WHO European Region over the past 20 years: virological
619	surveillance 1996 to 2016. Euro Surveill. 2018 Jan;23(1):17-00302. doi: 10.2807/1560-
620	7917.ES.2018.23.1.17-00302.
621	41. Fage C, Hénaut M, Carbonneau J, Piret J, Boivin G. Influenza A(H1N1)pdm09 Virus but
622	Not Respiratory Syncytial Virus Interferes with SARS-CoV-2 Replication during
623	Sequential Infections in Human Nasal Epithelial Cells. Viruses. 2022 Feb 15;14(2):395.
624	doi: 10.3390/v14020395.
625	42. Piret J, Boivin G. Viral Interference between Respiratory Viruses. Emerg Infect Dis. 2022
626	Feb;28(2):273-281. doi: 10.3201/eid2802.211727.

628	Table 1. Literature review of a	articles reporting on the r	umber of influenza B/Yamag	gata virus detections f	rom January 1 st , 2020.
-----	---------------------------------	-----------------------------	----------------------------	-------------------------	-------------------------------------

Author, year	Country or world region	Start of observation period	End of observation period	N respiratory specimens	N influenza	N influenza B	N influenza B characterized	N influenza B Yamagata		
Observation period from <u>befor</u>	Observation period from <u>before 2019</u> to <u>2020</u>									
Soldevila N et al, 2022 ^(a)	Spain	2010, ns	2020, ns	NA	NA	NA	1,159	955		
Murillo-Zamora E et al, 2021	Mexico	2016, Oct	2020, Apr	NA	4,678	808	632	283		
Observation period from 2019	to <u>2020</u>									
Korsun N et al, 2021	Bulgaria	2019, Oct	2020, Mar	1,387	610	138	138	0		
Panatto D et al, 2021	Italy	2019, Nov	2020, Feb	1,683	477	119	53	1		
Pablo-Marcos D et al, 2020	Spain	2019, Nov	2020, Mar	NA	652	180	167	0		
Miron VD et al, 2021	Romania	2019, Nov	2020, Mar	1,042	516	244	239	0		
Hu W et al, 2021	USA	2019, w45	2020, w13	28,176	5,529	2,336	862	6		
Omer I et al, 2022	Israel	2019, w46	2020, w11	1,769	973	354	NA	0		
Olson SM et al, 2022	USA	2019, Dec	2020, Apr	291	159	61	39	0		
Auvinen R et al, 2022	Finland	2019, Dec	2020, Jun	244	33	2	2	0		
Kuzmanovska M et al, 2021	Macedonia	2019, ns	2020, ns	NA	251	NA	NA	0		
Wagatsuma K et al, 2022 ^(a)	Japan	2019, ns	2020, ns	NA	159	53	53	0		
Observation period from 2019	Observation period from 2019 to 2021 or 2022									

Heinzinger S et al. 2021	Germany	2019, w38	2020, w14	1,376	517	153	151	22				
Hemzinger 5 et al, 2021		2020, w38	2021, w14	470	3	1	1	0				
		2019, Oct	2020, Apr	NA	4,836	1,910	1,843	92				
Ríos-Silva M et al, 2022	Mexico	2020, Oct	2021, Apr	NA	0	-	-	-				
		2021, Oct	2022, Apr	NA	816	7	4	0				
Observation period entirely in	<u>2020</u>											
Suntronwong N et al, 2021	Thailand	2020, Jan	2020, Mar	NA	349	NA	NA	0				
da Costa JC et al, 2022	Brazil	2020, Jan	2020, Mar	NA	NA	9	9	0				
Melidou A et al, 2020	WHO Euro	2020, w1	2020, w20	NA	1,691	397	397	1				
				Observation period from <u>2020</u> to <u>2021 or 2022</u>								
Observation period from 2020	to <u>2021 or 202</u>	2										
Observation period from 2020	<i>to <u>2021 or 202</u></i> Northern	<u>2</u> 2020, Jan	2020, Dec	177,987	11,742	2,100	2,093	42				
Observation period from 2020	to <u>2021 or 202</u> Northern China	<u>2</u> 2020, Jan 2021, Jan	2020, Dec 2021, Dec	177,987 220,011	11,742 12,117	2,100 12,106	2,093 12,087	42 13				
<i>Observation period from 2020</i> Huang WJ et al, 2022	to <u>2021 or 202</u> Northern China Southern	2 2020, Jan 2021, Jan 2020, Jan	2020, Dec 2021, Dec 2020, Dec	177,987 220,011 294,656	11,742 12,117 14,698	2,100 12,106 6,817	2,093 12,087 6,719	42 13 15				
<i>Observation period from 2020</i> Huang WJ et al, 2022	to <u>2021 or 202</u> Northern China Southern China	2 2020, Jan 2021, Jan 2020, Jan 2021, Jan	2020, Dec 2021, Dec 2020, Dec 2021, Dec	177,987 220,011 294,656 336,851	11,742 12,117 14,698 25,227	2,100 12,106 6,817 25,163	2,093 12,087 6,719 24,966	42 13 15 13				
Observation period from 2020 Huang WJ et al, 2022	to <u>2021 or 202</u> Northern China Southern China Melbourne	2 2020, Jan 2021, Jan 2020, Jan 2021, Jan 2020, Jan	2020, Dec 2021, Dec 2020, Dec 2021, Dec 2020, Dec	177,987 220,011 294,656 336,851 NA	11,742 12,117 14,698 25,227 2,021	2,100 12,106 6,817 25,163 NA	2,093 12,087 6,719 24,966 65	42 13 15 13 2				
<i>Observation period from 2020</i> Huang WJ et al, 2022 O'Neill G et al, 2022	to <u>2021 or 202</u> Northern China Southern China Melbourne WHO- CCRI	2 2020, Jan 2021, Jan 2020, Jan 2021, Jan 2020, Jan 2021, Jan	2020, Dec 2021, Dec 2020, Dec 2021, Dec 2020, Dec 2020, Dec 2021, Dec	177,987 220,011 294,656 336,851 NA NA	11,742 12,117 14,698 25,227 2,021 372	2,100 12,106 6,817 25,163 NA NA	2,093 12,087 6,719 24,966 65 13	42 13 15 13 2 0				
Observation period from 2020 Huang WJ et al, 2022 O'Neill G et al, 2022	to <u>2021 or 202</u> Northern China Southern China Melbourne WHO- CCRI	2 2020, Jan 2021, Jan 2020, Jan 2021, Jan 2020, Jan 2021, Jan 2021, Jan	2020, Dec 2021, Dec 2020, Dec 2021, Dec 2020, Dec 2021, Dec 2021, Dec 2021, May	177,987 220,011 294,656 336,851 NA NA NA	11,742 12,117 14,698 25,227 2,021 372 6	2,100 12,106 6,817 25,163 NA NA 6	2,093 12,087 6,719 24,966 65 13 6	42 13 15 13 2 0 0				

Observation period in <u>2021</u> or from <u>2021 to 2022</u>								
Peck H et al, 2023	Australia	2021, Jan	2021, Oct	15,026 ^(b)	42	10	10	0
Chon I et al, 2023	Myanmar	2021, Oct	2021, Dec	414	16	3	3	0
Merced-Morales A et al, 2022	USA	2021, Oct	2022, Jun	877,928	24,432	126	41	1 (c)
Melidou A et al, 2022	WHO Euro	2021, w40	2022, w10	NA	55,049	1,603	15	7 ^(d)
Sominina A et al, 2022 ^(a)	Russia	2021, ns	2022, ns	137,161	8,637	275	275	0
Song SX et al, 2022 ^(a)	China	2021, ns	2022, ns	26,754	7,250	7,250	7,250	0

629

630 N: number of reported cases. WHO-CCRI: World Health Organization - Collaborating Centre for Reference and Research on Influenza

- 631 ^(a) The observation period was reported as the "season" (namely, the season 2019-2020 in Kuzmanovska et al. and Wagatsuma et al.; the season 2021-2022 in
- 632 Sominina et al. and Song et al.; and the seasons 2010-2020 in Soldevila et al.).
- 633 ^(b) The specimens were collected from travellers arriving on repatriation flights..
- 634 ^(c) Other B/Yamagata detections were linked to LAIV, while only 1 was not tested.
- 635 ^(d) All reported 7 B/Yamagata were from Scotland and coincided with LAIV vaccination campaign, but further testing was not performed

Table 2. WHO-FluNet: number of influenza B Yamagata detections (overall and by country) in 2020 (weeks 1-17 or 18-53), 2021,

- 637 2022, and 2023 until week 19, and rate of detections per 100,000 processed specimens and influenza-, influenza B-, and characterized
- 638 influenza B-positive detections.

		Influ	enza B Yamaş	gata detections		
Year and period	Influenza B Yamagata detections	processed specimens ^(a)	influenza- positive detections	influenza B- positive detections	influenza B-positive detections, lineage characterized	Detections by country and week
2020, weeks 1-17	351	14.88	75.27	211.54	1386.47	n = 117: USA (weeks 1-13), n = 67: Mexico (weeks 1-14), n = 54: China (weeks 1-17), n = 18: Norway (weeks 1-8), n = 14: Dominican Republic (weeks 2-9), n = 10: France (weeks 2-12), n < 10: 24 countries
2020, weeks 18-52	13	0.40	269.93	604.09	2245.25	n = 8 : USA (weeks 44-49), n = 4 : China (weeks 19-51), n = 1 : Afghanistan (week 45)
2021	42	0.51	36.10	123.55	144.33	n = 32: China (weeks 1-39), n = 3: India (week 41), n = 1: Afghanistan (week 1), Niger (week 1), Ghana (week 4), Bulgaria (week 8), Ivory Coast (week 8), Mexico (week 24), USA (week 39)
2022	3	0.03	0.31	4.74	8.67	n = 2 : Germany (weeks 12-13), n = 1 : North Korea (week 43)
2023, weeks 1-33	6	0.09	1.40	5.25	33.61	n = 5 : Cameroon (weeks 23-31), n = 1 : Cuba (week 11)

639

^(a) Calculated over the total of countries and weeks in which the number of processed specimens was reported.

640 Table 3. Global Influenza Hospital Surveillance Network: number of influenza detections (overall, type B, characterized type B, and

Period	Influenza- positive detections	Influenza B- positive detections	Influenza B- positive detections, lineage characterized	Influenza B/Yamagata detections by country and week
2020, weeks 1-17	3,772	1,449	639	6 (France weeks 1 and 9, India week 5, Mexico weeks 6 and 9, Russia week 12)
2020, weeks 18-53	15	5	1	1 (India week 51)
2021	875	149	33	0
2022	2,961	241	173	0
2023, weeks 1-27	967	211	132	0

641 B/Yamagata) in 2020 (weeks 1-17 or 18-53), 2021, 2022, and 2023until week 29.

Table 4. Number of respiratory specimens tested for influenza, and number of reported influenza B/Yamagata detections, from 643

national influenza surveillance systems webpages worldwide (see text for a complete list of countries that were included). 644

Year and period	Influenza B Yamagata detections	Detections by country and week	Influenza positive specimens by country and surveillance system
2019, week 40 to 2020, week 20	n = 269	 n=1 : Spain (week 1/2020), Netherlands (week 8/2020), England (week 6/2020), Portugal (week 48/2019), Russia (week 05/2020), Germany, (unknown week) n=239 : USA (weeks 40/2019 to 13/2020) n=24 : France (weeks 48/2019 to 11/2020) 	 n=2,579 : Spain (Virus characterisation) n=207 : Netherland (GP surveillance) n=1,204 : England (Virus characterisation) n=303 : Germany (Virus characterisation) n=349 : Portugal (emergency and obstetrics wards) n=16,649 : Russia (National Influenza Centres and network of Regional Base Laboratories) n=45,898 : USA (Public Health Laboratories) n=1,195 : France (GP surveillance)
2020, week 35 to 2021, week 39	n = 10	n=1 : Australia (week 37-38/2020) n=9 : USA (weeks 44-49/2020, 39/2021)	 n=306 : Australia (World Health Organization Collaborating Centre for Reference and Research on Influenza) n=352 : USA (Public Health Laboratories)
2021, week 40 to 2022, week 39	n = 1	n=1 : USA (week 46/2021)	n=26,322 : USA (Public Health Laboratories)
GP: general practitio	oners		·

GP: general practitioners 645

It is made available under a CC-BY-NC-ND 4.0 International license .

- **Figure 1**. Flow-chart of the systematic literature review of articles reporting the number of
- 647 influenza B/Yamagata virus detections from January 1st, 2020, until March 20th, 2023.

648





